US companies hoard genetic data, European scientists urge greater openness

| November 1, 2012
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The proprietary collections of genetic testing data amassed by US diagnostics companies effectively give them competitive advantages and can negatively impact the testing market and make it harder for doctors to interpret patient results, according to a paper published yesterday in the online edition of the European Journal of Human Genetics.

Genetic testing companies in the US, such as Myriad Genetics, have collected proprietary information from their patients that enhances their ability to interpret test results, but they can keep others from accessing such important interpretive information, according to the paper.

View the original article here: Using Myriad as Case Study, Paper Urges Europe to Ensure Greater Access to genetic test data

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend